The U.S. Food and Drug Administration announced on Tuesday that it had approved Abbott Laboratories’ (ABT.N) new tab glucose monitor, making it the first gadget that continually checks blood sugar and ketone levels.
For those with diabetes who are two years of age or older, the Libre Duo 10 Day device is intended to be worn for ten days.
The biowearable is intended to warn users of growing ketones, which can cause a diabetic ketoacidosis (DKA) emergency, a dangerous health issue for diabetics.
Abbott’s equipment continually monitors both ketone and glucose levels, displaying real-time trends, in contrast to previous ketone tests that only provided isolated, one-time measurements.
Before DKA turns into a medical emergency, patients and caregivers may be able to identify rising ketones with the aid of the device’s automatic warnings.
According to Chris Scoggins, executive vise president of Abbott’s diabetes care division, “if glucose is the speedometer, ketones are like the check engine light—providing an alert that may need attention.”
Scoggins continued, “The device provides a more comprehensive picture to help people with diabetes make more informed decisions by combining both glucose and ketone levels into a single dashboard.”
Abbott is collaborating with top pump manufacturers to make it possible for automated insulin delivery devices to communicate with the sensors.
According to the business, the device interfaces with the Libre app, and in 2027, Tandem and Insulet devices should be compatible with Libre Duo 10 Day.
